In this article
FDA Approval of Bosutinib for Paediatric Ph+ CML
Nov 2023: For paediatric patients aged one year and above with chronic phase (CP) Ph+ chronic myelogenous leukaemia (CML), either newly diagnosed (ND) or resistant or intolerant (R/I) to previous therapy, the Food and Drug Administration has approved bosutinib (Bosulif, Pfizer). Additionally, a novel capsule dosage form with 50 mg and 100 mg concentrations was approved by the FDA.
BCHILD Clinical Trial Efficacy and Results
The BCHILD trial (NCT04258943) assessed the efficacy of bosutinib in paediatric patients with ND CP Ph+ CML and R/I CP Ph+ CML. The trial was multicenter, nonrandomized, and open-label, with the goals of determining a recommended dose, estimating safety and tolerability, assessing efficacy, and assessing bosutinib pharmacokinetics in this patient population. The trial included 21 patients with ND CP Ph+ CML treated at 300 mg/m2 once daily and 28 patients with R/I CP Ph+ CML treated with bosutinib at 300 mg/m2 to 400 mg/m2 orally once daily.
Major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR) were the primary efficacy outcome metrics. The major (MCyR) and complete (CCyR) cytogenetic responses for paediatric patients with ND CP Ph+ CML were 76.2% (95% CI: 52.8, 91.8) and 71.4% (95% CI: 47.8, 88.7), respectively. 28.6% (95% CI: 11.3, 52.3) was the MMR, and 14.2 months was the median follow-up period (range: 1.1, 26.3 months).
The major (MCyR) and complete (CCyR) cytogenetic responses for paediatric patients with R/I CP Ph+ CML were 82.1% (95% CI: 63.1, 93.9) and 78.6% (95% CI: 59, 91.7), respectively. 50% (95% CI: 30.6, 69.4) was the MMR. Two of the 14 patients who reached MMR lost MMR after receiving treatment for 13.6 and 24.7 months, respectively. A follow-up of 23.2 months was the median (range: 1, 61.5 months).
Safety Profile and Paediatric Dosage Guidelines
Among paediatric patients, diarrhoea, abdominal pain, vomiting, nausea, rash, lethargy, hepatic dysfunction, headache, pyrexia, decreased appetite, and constipation were the most frequently reported side effects (≥20%). In paediatric patients, increased creatinine, increased alanine aminotransferase or aspartate aminotransferase, decreased white blood cell count, and decreased platelet count were the most prevalent laboratory abnormalities that worsened from baseline (≥45%).
For paediatric patients with ND CP Ph+ CML, the recommended dosage of bosutinib is 300 mg/m2 orally once daily with food; for paediatric patients with R/I CP Ph+ CML, the recommended dosage is 400 mg/m2 orally once daily with food. The contents of the capsules can be combined with yoghurt or applesauce for individuals who are unable to swallow them.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.